Figure S1 from PLT012, a Humanized CD36-Blocking Antibody, Is Effective for Unleashing Antitumor Immunity Against Liver Cancer and Liver Metastasis

Puntos clave

• MAIN FINDING: PLT012, a humanized CD36-blocking antibody, is effective in boosting antitumor immunity against liver cancer.
• KEY EVIDENCE: Treatment resulted in significant tumor reduction in syngeneic murine models, supporting its antitumor properties.
• APPROACH: The study assessed the effects of PLT012 through experiments with subcutaneous tumors in murine models.
• SIGNIFICANCE: This research highlights a promising immunotherapy approach for treating liver cancer and metastasis.